Organization | University of Leeds

University of Leeds Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Leeds United Kingdom (1824)

Organization Overview

First Clinical Trial

1993

NCT00002582

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Bradford Royal Infirmary | Bradford Teaching Hospitals NHS Foundation Trust | Chapel Allerton Hospital, Leeds | Clinical Trials Research Unit, Leeds | Cookridge Hospital | Institute of Rheumatic & Musculoskeletal Medicine, Chapel Allerton Hospital | Julia Brown | Leeds Cancer Centre at St. James's University Hospital | Leeds General Infirmary | Leeds Hospital - Leeds - UK | Leeds Institute of Cancer and Pathology, Wellcome Trust Brenner Buidling, St James Univeristy Hospital, Leeds | Leeds Institute of Clinical Trials Research | Leeds Institute of Molecular Medicine, University of Leeds | Leeds Institute of Rheumatic and Musculoskeletal Medicine | Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK | Leeds Partnerships NHS Foundation Trust | Leeds Teaching Hospitals NHS Trust, Leeds, UK | Leeds University | National Co-Coordinating Investigator - St James's University Hospital UK | Prof Jamie Cavenagh | St James' Institute of Oncology, Leeds, UK | St James's Institute of Oncology, St James's University Hospital, Leeds. | St James's University Hospital | St James University Hospital, Leeds, UK | The Leeds Teaching Hospitals NHS Trust | The University of Leeds | Univeristy of Leeds, CTRU | University ofLeeds | University of Leeds | University of Leeds, United Kingdom

Active Ingredients

Drugs in Phase 4 Trials (34)

abatacept (orencia) (2 trials)

adalimumab (humira) (3 trials)

carbamazepine (tegretol) (1 trial)

certolizumab pegol (cimzia) (1 trial)

clobazam (onfi) (1 trial)

clonazepam (klonopin) (1 trial)

dapagliflozin (farxiga) (1 trial)

etanercept (enbrel) (5 trials)

ethosuximide (zarontin) (1 trial)

fentanyl (Innovar) (1 trial)

folic acid (2 trials)

golimumab (simponi) (2 trials)

hydroxychloroquine (plaquenil) (3 trials)

infliximab (remicade) (3 trials)

interferon alpha-2b (Intron-A) (2 trials)

lacosamide (vimpat) (1 trial)

lamotrigine (lamictal) (1 trial)

levetiracetam (keppra) (1 trial)

levobupivacaine (chirocaine) (1 trial)

liraglutide (victoza) (1 trial)

meperidine (demerol) (1 trial)

methotrexate (4 trials)

methylprednisolone (medrol) (4 trials)

naltrexone (revia) (4 trials)

nitrazepam (Mogadon) (1 trial)

phenytoin (mesantoin) (1 trial)

pioglitazone (actos) (1 trial)

remifentanil (ultiva) (1 trial)

ribavirin (virazole) (1 trial)

rituximab (rituxan) (5 trials)

semaglutide (Ozempic) (1 trial)

sulfasalazine (azulfidine) (2 trials)

telaprevir (incivek) (1 trial)

tocilizumab (actemra) (1 trial)

Drugs in Phase 3 Trials (55)

autologous hematopoietic stem cells (2 trials)

autologous mononuclear stem cell (1 trial)

bevacizumab (avastin) (1 trial)

bone autograft (1 trial)

bone marrow derived mesenchymal stem cells (1 trial)

bortezomib (velcade) (5 trials)

bupivacaine (Exparel) (1 trial)

busulfan (Myleran) (1 trial)

canrenone (Contaren) (1 trial)

capecitabine (xeloda) (1 trial)

carboplatin (paraplatin) (2 trials)

carfilzomib (kyprolis) (1 trial)

carmustine (bicnu) (1 trial)

chlorambucil (Leukeran) (1 trial)

cisplatin (platinol) (7 trials)

cladribine (leustatin) (1 trial)

cyclophosphamide (cytoxan) (12 trials)

cyclosporine (sandimmune) (1 trial)

dactinomycin (cosmegen) (1 trial)

dexamethasone (2 trials)

doxorubicin (Doxil) (6 trials)

etoposide (vepesid) (3 trials)

fludarabine (fludara) (2 trials)

fluorouracil (efudex) (3 trials)

goserelin (zoladex) (1 trial)

icosapent ethyl (vascepa) (2 trials)

idarubicin (idamycin) (1 trial)

ifosfamide (ifex) (1 trial)

irinotecan (Camptosar) (2 trials)

ixazomib (ninlaro) (3 trials)

lenalidomide (revlimid) (6 trials)

leucovorin (3 trials)

leuprolide (lupron) (1 trial)

melphalan (alkeran) (7 trials)

metyrapone (metopirone) (1 trial)

mifepristone (mifeprex) (1 trial)

mitomycin (mutamycin) (2 trials)

ondansetron (zofran) (1 trial)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (1 trial)

Pagibaximab (aurograb) (1 trial)

panitumumab (vectibix) (1 trial)

prednisone (meticorten) (2 trials)

rimonabant (1 trial)

sargramostim (leukine) (3 trials)

simvastatin (zocor) (1 trial)

tamoxifen (nolvadex) (1 trial)

temsirolimus (torisel) (2 trials)

testosterone (delatestryl) (1 trial)

thalidomide (Thalomid) (3 trials)

urea (9 trials)

vincristine (oncovin) (9 trials)

vinorelbine (navelbine) (3 trials)

vorinostat (zolinza) (2 trials)

zoledronic acid (zometa) (2 trials)

Drugs in Phase 2 Trials (36)

acetylsalicylic acid (aspirin) (1 trial)

alemtuzumab (campath) (2 trials)

amiloride (midamor) (1 trial)

apremilast (otezla) (1 trial)

azacitidine (vidaza) (1 trial)

azd4017 (1 trial)

bcx9930 (1 trial)

bumetanide (bumex) (1 trial)

cannabidiol (Epidiolex) (2 trials)

cefuroxime (zinacef) (2 trials)

daratumumab (darzalex) (1 trial)

docetaxel (taxotere) (1 trial)

emi-137 (1 trial)

Filgrastim (neupogen) (1 trial)

fluoxetine (prozac) (1 trial)

gemcitabine (gemzar) (1 trial)

glucarpidase (voraxaze) (1 trial)

lisinopril (zestril) (1 trial)

lomustine (2 trials)

mitoxantrone (novantrone) (1 trial)

miv-711 (2 trials)

mrx-4dp0004 (1 trial)

naloxone (narcan) (1 trial)

ono-4474 (1 trial)

panobinostat (farydak) (1 trial)

pembrolizumab (keytruda) (4 trials)

pomalidomide (pomalyst) (2 trials)

reolysin (2 trials)

riluzole (rilutek) (1 trial)

scib1 (1 trial)

sodium chloride (2 trials)

temozolomide (temodar) (1 trial)

tetrahydrocannabinol (3 trials)

vinblastine (velban) (1 trial)

vitamin c (3 trials)

vitamin d3 (2 trials)

Drugs in Phase 1 Trials (6)

azd1390 (1 trial)

cremophor (1 trial)

fludeoxyglucose f-18 (1 trial)

gsk-1070916 (1 trial)

olaparib (lynparza) (1 trial)

pha-793887 (1 trial)

Drugs in Other Trials (32)

125-iodine (1 trial)

almond (1 trial)

amikacin (Amikin) (1 trial)

amlodipine (norvasc) (1 trial)

amoxicillin (1 trial)

anthrocyanins (1 trial)

arabinoxylan (1 trial)

arginine (1 trial)

bendroflumethiazide (naturetin) (1 trial)

beta-glucans (2 trials)

casein (1 trial)

codeine (Phenergan) (1 trial)

coffee (1 trial)

colistin (1 trial)

docosahexaenoic acid (1 trial)

hydrolysed whey protein (1 trial)

ivabradine (corlanor) (2 trials)

monofluorophosphate (1 trial)

normocoxib (normoxocin) (1 trial)

Olesoxime (1 trial)

orange juice (2 trials)

palladium (1 trial)

pineapple (1 trial)

pomegranate (1 trial)

sulforaphane (1 trial)

tobramycin (nebcin) (1 trial)

turmeric (1 trial)

valsartan (diovan) (1 trial)

vitis vinifera (1 trial)

whey protein (1 trial)

zinc sulfate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Abortion, Missed (Phase 3)

Abortion, Spontaneous (Phase 3)

Arthritis (Phase 4)

Arthritis, Psoriatic (Phase 3)

Arthritis, Rheumatoid (Phase 4)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 3)

Carcinoma, Transitional Cell (Phase 2)

Central Nervous System Neoplasms (Phase 2)

Chronic Pain (Phase 2)

Colonic Neoplasms (Phase 3)

Colorectal Neoplasms (Phase 3)

Communicable Diseases (Phase 3)

Constipation (Phase 2)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diarrhea (Phase 3)

Ependymoma (Phase 2)

Epilepsy (Phase 4)

Erectile Dysfunction (Phase 3)

Fallopian Tube Neoplasms (Phase 3)

Frailty (Phase 3)

Glioblastoma (Phase 2)

Heart Failure (Phase 2)

Hepatitis C (Phase 4)

Hypogonadism (Phase 3)

Infarction (Phase 3)

Infections (Phase 3)

Intestinal Neoplasms (Phase 1)

Irritable Bowel Syndrome (Phase 3)

Kidney Neoplasms (Phase 2)

Leg Ulcer (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Leukemia, Myelomonocytic, Juvenile (Phase 2)

Liver Neoplasms (Phase 3)

Lung Neoplasms (Phase 2)

Lupus Erythematosus, Cutaneous (Phase 2)

Lupus Erythematosus, Discoid (Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell (Phase 1)

Lymphoma, T-Cell, Peripheral (Phase 1)

Medulloblastoma (Phase 2)

Melanoma (Phase 2)

Mesothelioma (Phase 3)

Mucositis (Phase 2)

Multiple Myeloma (Phase 3)

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Chronic Progressive (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Myocardial Infarction (Phase 3)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 3)

Neoplasms, Second Primary (Phase 3)

Nervous System Neoplasms (Phase 2)

Neuroblastoma (Phase 3)

Neuroectodermal Tumors (Phase 2)

Neuroectodermal Tumors, Primitive (Phase 2)

Neurotoxicity Syndromes (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 3)

Osteosarcoma (Phase 3)

Ovarian Neoplasms (Phase 3)

Peritoneal Neoplasms (Phase 3)

Plasmacytoma (Phase 3)

Reperfusion Injury (Phase 3)

Sarcoma (Phase 3)

Sclerosis (Phase 3)

Seizures (Phase 2)

Skin Neoplasms (Phase 2)

Spondylarthropathies (Phase 2)

Staphylococcal Infections (Phase 3)

ST Elevation Myocardial Infarction (Phase 3)

Surgical Wound Infection (Phase 2)

Syndrome (Phase 3)

Ulcer (Phase 2)

Ureteral Neoplasms (Phase 2)

Urethral Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Varicose Ulcer (Phase 2)

Waldenstrom Macroglobulinemia (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 125
# of Trial APIs: 163